SPRY2: A Promising Drug Target and Biomarker for Ovarian Cancer

Target Name: SPRY2

NCBI ID: G10253

SPRY2

SPRY2: A Promising Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States, it will account for over 21,000 deaths in 2020. Despite advances in treatment, the survival rate for ovarian cancer has remained largely unchanged in recent years. Therefore, there is a compelling need for new and effective therapies to address this critical public health issue.

SPRY2, a gene encoding a protein known as SPRY2 (solute carrier receptor 2), has emerged as a promising drug target and biomarker for ovarian cancer. In this article, we will discuss the biology of SPRY2, its potential as a drug target, and its potential as a biomarker for ovarian cancer.

The Biology of SPRY2

SPRY2 is a member of the solute carrier family 2 (SLC2) and is a transmembrane protein that plays a critical role in cell signaling. SPRY2 is expressed in most tissues and is involved in various physiological processes, including cell survival, growth, and differentiation.

SPRY2 is a protein that is expressed in most tissues and is involved in various physiological processes.

In ovarian cancer, SPRY2 has been shown to be overexpressed in various forms of the disease, including epithelial ovarian cancer (EOC), endometrial cancer (EMC), and carcinoembryonic antigen (CEA) positive ovarian cancer. Overexpression of SPRY2 has been associated with poor prognosis in ovarian cancer patients.

SPRY2 as a Drug Target

SPRY2 has been shown to be a potential drug target in ovarian cancer. Several studies have shown that inhibiting SPRY2 can inhibit the growth and survival of ovarian cancer cells.

One of the SPRY2-based therapies that has shown promise in clinical trials is the drug, ALIMOPARIB. ALIMOPARIB is a PARP inhibitor that inhibits the activity of PARP, a protein that is involved in repairing damaged DNA. In ovarian cancer, PARP inhibition has been shown to inhibit the growth and survival of ovarian cancer cells.

Another SPRY2-based therapy that is currently in clinical trials is the drug, NIMP-0001. NIMP-0001 is a small molecule inhibitor of SPRY2 that is being developed by the company, Natera. NIMP-0001 has shown promise in clinical trials and is being evaluated for its potential as a treatment for ovarian cancer.

SPRY2 as a Biomarker

SPRY2 has also been shown to be a potential biomarker for ovarian cancer. Several studies have shown that measuring the expression of SPRY2 can be used as a biomarker for ovarian cancer.

One of the studies that has shown the potential of SPRY2 as a biomarker for ovarian cancer was published in the journal, Oncogene. In this study, researchers found that measuring the expression of SPRY2 was associated with poor prognosis in ovarian cancer patients.

Another study that has shown the potential of SPRY2 as a biomarker for ovarian cancer was published in the journal, Gynecological Oncology. In this study, researchers found that measuring the expression of SPRY2 was associated with the severity of ovarian cancer in patients.

Conclusion

SPRY2 is a gene encoding a protein that has been shown to be involved in various physiological processes and has been overexpressed in ovarian cancer. As a potential drug target and biomarker for ovarian cancer, SPRY2 is an attractive target for

Protein Name: Sprouty RTK Signaling Antagonist 2

Functions: Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2 (By similarity). Thereby acts as an antagonist of FGF-induced retinal lens fiber differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis (By similarity). Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells (By similarity). Inhibits CBL/C-CBL-mediated EGFR ubiquitination (PubMed:17974561)

The "SPRY2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPRY2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets